{"organizations": [], "uuid": "922b05597493ed49389fd9783ca7f22bc328074e", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-adamis-pharmaceuticals-announces-f/brief-adamis-pharmaceuticals-announces-fda-acceptance-for-review-for-the-supplemental-new-drug-application-idUSASB0C57Q", "country": "US", "domain_rank": 408, "title": "BRIEF-Adamis Pharmaceuticals Announces FDA Acceptance For Review For The Supplemental New Drug Application", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-02-12T16:08:00.000+02:00", "replies_count": 0, "uuid": "922b05597493ed49389fd9783ca7f22bc328074e"}, "author": "", "url": "https://www.reuters.com/article/brief-adamis-pharmaceuticals-announces-f/brief-adamis-pharmaceuticals-announces-fda-acceptance-for-review-for-the-supplemental-new-drug-application-idUSASB0C57Q", "ord_in_thread": 0, "title": "BRIEF-Adamis Pharmaceuticals Announces FDA Acceptance For Review For The Supplemental New Drug Application", "locations": [], "entities": {"persons": [{"name": "adamis", "sentiment": "none"}], "locations": [], "organizations": [{"name": "fda", "sentiment": "negative"}, {"name": "brief-adamis pharmaceuticals announces fda", "sentiment": "negative"}, {"name": "supplemental new drug application reuters", "sentiment": "none"}, {"name": "adamis pharmaceuticals corp", "sentiment": "none"}, {"name": "adamis pharmaceuticals corp", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "February 12, 2018 / 2:08 PM / Updated 12 minutes ago BRIEF-Adamis Pharmaceuticals Announces FDA Acceptance For Review For The Supplemental New Drug Application Reuters Staff 1 Min Read \nFeb 12 (Reuters) - Adamis Pharmaceuticals Corp: \n* ADAMIS PHARMACEUTICALS ANNOUNCES FDA ACCEPTANCE FOR REVIEW FOR THE SUPPLEMENTAL NEW DRUG APPLICATION OF ITS LOW DOSE SYMJEPI PRODUCT CANDIDATE \n* ADAMIS PHARMACEUTICALS CORP - FDA FURTHER INDICATED THAT NO POTENTIAL REVIEW ISSUES WERE IDENTIFIED \n* ADAMIS PHARMACEUTICALS CORP - FDA FURTHER INDICATED THAT NO POTENTIAL REVIEW ISSUES WERE IDENTIFIED \n* ADAMIS PHARMACEUTICALS CORP - FDA INDICATED IF NO MAJOR DEFICIENCIES IDENTIFIED, THEY ARE TARGETING SEPTEMBER 3, 2018 TO COMMUNICATE PROPOSED LABELING Source text for Eikon: Further company coverage: (Bangalore.newsroom@thomsonreuters.com)", "external_links": [], "published": "2018-02-12T16:08:00.000+02:00", "crawled": "2018-02-12T16:22:34.003+02:00", "highlightTitle": ""}